Lannett's deal call for another pharmaceutical company to purchase and distribute under a private label a limited number of certain other Lannett owned generic drug products.
WBA's fourth quarter sales from continuing operations decreased 5.3% from the year-ago quarter to $32.4 billion, a decrease of 3.2% on a constant currency basis.